GENTIAN VIOLET: WHAT WE KNOW AND WHAT IS AHEAD OF US

被引:3
作者
Dragan, Jedrzej [1 ]
Michalak, Sylwia Sulimiera [1 ]
机构
[1] Univ Zielona, Fac Med & Hlth Sci, Gora, Poland
来源
ACTA POLONIAE PHARMACEUTICA | 2019年 / 76卷 / 03期
关键词
p53; crystal violet; gentian violet; fungal infection; bacterial infection; STAPHYLOCOCCUS-AUREUS; OROPHARYNGEAL; CANDIDIASIS; METABOLISM; INFECTION; NYSTATIN; THERAPY;
D O I
10.32383/appdr/102482
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
At present, the only active substance of Gentian Violet (GV) is methylrosaniline - a triphenylmethane dye of which amino group contains 2 methyl groups. GV can be used to treat uncomplicated bacterial and/or yeast infections, support antibiotic therapy of more severe infections, but also to protect medical equipment against colonization by microorganisms. In the light of recent studies, there are many new possibilities for GV application. It has been shown to be effective in the treatment of viral infections, some chronic skin diseases and oncology. GV can induce apoptosis of tumor cells among others by elevating caspase 8, inhibiting NADPH oxidases, decreasing mitochondrial thioredoxin 2 or inhibiting STAT3/SOX2 axis. Preclinical and in vitro studies have also demonstrated GV efficacy in the treatment of breast cancer, melanoma tumors and cutaneous T-cell lymphoma. There is no unambiguous evidence indicating the toxicity of GV, whereas its safety has been proven by its long history of use, its inclusion in numerous guidelines and its legal trade and distribution with no specific approval requested in many countries around the world. The article gathers the available knowledge about GV and its potential use in the future.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 50 条
  • [21] Chlamydia pneumoniae and atherosclerosis -: what we know and what we don't
    Ngeh, J
    Anand, V
    Gupta, S
    CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (01) : 2 - 13
  • [22] p53 family members and chemoresistance in cancer: what we know and what we need to know
    Gasco, M
    Crook, T
    DRUG RESISTANCE UPDATES, 2003, 6 (06) : 323 - 328
  • [23] Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
    Tadic, Marijana
    Cuspidi, Cesare
    Grassi, Guido
    Mancia, Giuseppe
    INTEGRATED BLOOD PRESSURE CONTROL, 2020, 13 : 63 - 69
  • [24] Carbonyl Sulfide (COS) in Terrestrial Ecosystem: What We Know and What We Do Not
    Li, Jiaxin
    Shen, Lidu
    Zhang, Yuan
    Liu, Yage
    Wu, Jiabing
    Wang, Anzhi
    ATMOSPHERE, 2024, 15 (07)
  • [25] Chronic vulvovaginal candidiasis: What we know and what we have yet to learn
    Fischer, Gayle
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2012, 53 (04) : 247 - 254
  • [26] Isolated distal deep vein thrombosis: what we know and what we are doing
    Palareti, G.
    Schellong, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (01) : 11 - 19
  • [27] Survey of paediatric intravenous fluid prescription: Are we safe in what we know and what we do?
    Keijzers, Gerben
    McGrath, Melissa
    Bell, Christa
    EMERGENCY MEDICINE AUSTRALASIA, 2012, 24 (01) : 86 - 97
  • [28] Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment
    Pecanha, Paulo Mendes
    Pecanha-Pietrobom, Paula Massaroni
    Grao-Velloso, Tania Regina
    Rosa Junior, Marcos
    Falqueto, Aloisio
    Goncalves, Sarah Santos
    JOURNAL OF FUNGI, 2022, 8 (10)
  • [29] Honey and Wound Healing: What Do We Really Know?
    Durieux, Marcel
    AMERICAN BEE JOURNAL, 2013, 153 (10): : 1091 - 1094
  • [30] Coccidioidomycosis and Host Microbiome Interactions: What We Know and What We Can Infer from Other Respiratory Infections
    Tejeda-Garibay, Susana
    Hoyer, Katrina K.
    JOURNAL OF FUNGI, 2023, 9 (05)